Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
Introduction Prostate cancer is the second most common cancer in men worldwide. When the disease becomes resistant to androgen-deprivation therapy, treatment options are sparse. To address the high medical need in castration-resistant prostate cancer (CRPC), we generated a novel PSMAxCD3 bispecific...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 16, 2020
|
| In: |
BMJ open
Year: 2020, Volume: 10, Issue: 10, Pages: 1-9 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2020-039639 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bmjopen-2020-039639 Verlag, lizenzpflichtig, Volltext: https://bmjopen.bmj.com/content/10/10/e039639 
|
| Author Notes: | Jonas S. Heitmann, Juliane S. Walz, Martin Pflügler, Joseph Kauer, Richard F. Schlenk, Gundram Jung, Helmut R. Salih |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1757541012 | ||
| 003 | DE-627 | ||
| 005 | 20230426112712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210510s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2020-039639 |2 doi | |
| 035 | |a (DE-627)1757541012 | ||
| 035 | |a (DE-599)KXP1757541012 | ||
| 035 | |a (OCoLC)1341408661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Heitmann, Jonas S. |d 1988- |e VerfasserIn |0 (DE-588)1203641826 |0 (DE-627)1688653376 |4 aut | |
| 245 | 1 | 0 | |a Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma |c Jonas S. Heitmann, Juliane S. Walz, Martin Pflügler, Joseph Kauer, Richard F. Schlenk, Gundram Jung, Helmut R. Salih |
| 264 | 1 | |c October 16, 2020 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.05.2021 | ||
| 520 | |a Introduction Prostate cancer is the second most common cancer in men worldwide. When the disease becomes resistant to androgen-deprivation therapy, treatment options are sparse. To address the high medical need in castration-resistant prostate cancer (CRPC), we generated a novel PSMAxCD3 bispecific antibody termed CC-1. CC-1 binds to prostate-specific membrane antigen that is expressed on prostate cancer cells and tumour vessels, thereby allowing a dual anticancer effect. - Methods and analysis This first in human clinical study is a prospective and multicentre trial which enrols patients with metastatic CRPC after failure of established third-line therapy. CC-1 is applied after prophylactic interleukin-6 receptor blockade with tocilizumab (once 8 mg/kg body weight). Each patient receives at least one cycle of CC-1 over a time course of 7 days in an inpatient setting. If clinical benefit is observed, up to five additional cycles of CC-1 can be applied. The study is divided in two parts: (1) a dose escalation phase with intraindividual dose increase from 28 µg to the target dose of 1156 µg based on a modified fast titration design by Simon et al to determine safety, tolerability and the maximum tolerated dose (MTD) as primary endpoints and (2) a dose expansion phase with additional 14 patients on the MTD level of part (1) to identify first signs of efficacy. Secondary endpoints compromise overall safety, tumour response, survival and a translational research programme with, among others, the analysis of CC-1 half-life, the induced immune response, as well as the molecular profiling in liquid biopsies. - Ethics and dissemination The PSMAxCD3 study was approved by the Ethics Committee of The University Hospital Tübingen (100/2019AMG1) and the Paul-Ehrlich-Institut (3684/02). Clinical trial results will be published in peer-reviewed journals. - Trial registration numbers ClinicalTrials.gov Registry (NCT04104607) and ClinicalTrials.eu Registry (EudraCT2019-000238-20). | ||
| 650 | 4 | |a adult oncology | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a urological tumours | |
| 700 | 1 | |a Walz, Juliane S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pflügler, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kauer, Joseph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Jung, Gundram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salih, Helmut R. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d London : BMJ Publishing Group, 2011 |g 10(2020), 10, Artikel-ID e039639, Seite 1-9 |h Online-Ressource |w (DE-627)654747075 |w (DE-600)2599832-8 |w (DE-576)339269340 |x 2044-6055 |7 nnas |a Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:10 |g elocationid:e039639 |g pages:1-9 |g extent:9 |a Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bmjopen-2020-039639 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://bmjopen.bmj.com/content/10/10/e039639 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210510 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1757541012 |e 3927118826 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 10.05.2021"],"person":[{"role":"aut","family":"Heitmann","display":"Heitmann, Jonas S.","given":"Jonas S."},{"family":"Walz","role":"aut","given":"Juliane S.","display":"Walz, Juliane S."},{"display":"Pflügler, Martin","given":"Martin","family":"Pflügler","role":"aut"},{"role":"aut","family":"Kauer","given":"Joseph","display":"Kauer, Joseph"},{"role":"aut","family":"Schlenk","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich"},{"display":"Jung, Gundram","given":"Gundram","family":"Jung","role":"aut"},{"given":"Helmut R.","display":"Salih, Helmut R.","role":"aut","family":"Salih"}],"recId":"1757541012","language":["eng"],"name":{"displayForm":["Jonas S. Heitmann, Juliane S. Walz, Martin Pflügler, Joseph Kauer, Richard F. Schlenk, Gundram Jung, Helmut R. Salih"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"October 16, 2020"}],"relHost":[{"disp":"Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinomaBMJ open","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"issue":"10","extent":"9","pages":"1-9","text":"10(2020), 10, Artikel-ID e039639, Seite 1-9","year":"2020","volume":"10"},"language":["eng"],"pubHistory":["2011 -"],"note":["Gesehen am 02.10.20"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2599832-8"],"issn":["2044-6055"],"eki":["654747075"]},"title":[{"title_sort":"BMJ open","title":"BMJ open"}],"origin":[{"publisher":"BMJ Publishing Group","dateIssuedDisp":"2011-","dateIssuedKey":"2011","publisherPlace":"London"}],"recId":"654747075"}],"id":{"doi":["10.1136/bmjopen-2020-039639"],"eki":["1757541012"]},"physDesc":[{"extent":"9 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma","title":"Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma"}]} | ||
| SRT | |a HEITMANNJOPROTOCOLOF1620 | ||